PTC Therapeutics – Duchenne Muscular Dystrophy

Access Program Information

The expanded access program will provide access to treatment with deflazacort in children,
adolescent, and adult patients with DMD in the U.S. who are ineligible, unable, or otherwise
unwilling to enroll in a clinical study examining the efficacy of deflazacort while a new
drug application is under preparation and review. Enrollment is open to all eligible